Multiple Myeloma, how to sequence new therapies - Dr. Jesus Berdeja (Sep 30-Oct 1, 2022)

(25:31)

Jesus Berdeja | EHA 2018 | Summary of the CRB-401 phase I bb2121 CAR T-cell study

(1:45)

CAR T-CELL Therapy in Multiple Myeloma, When \u0026 How Effective - Dr. Jesus Berdeja(Sep 30-Oct 1, 2022)

(22:41)

New Indication for Sarclisa in Myeloma: What HCPs Need to Know – Dr. Jesus Berdeja

(2:56)

Dr. Berdeja on Maintenance Therapy in Multiple Myeloma

(1:25)

Jesus Berdeja, MD, describes how BCMA targeting differs from other CAR-T cell therapies

(1:7)

Know Your Myeloma Immunotherapy: Antibody Drug Conjugates with Dr. Jesus Berdeja

(57:55)

Dr. Berdeja Discusses Next Steps With bb2121 in Multiple Myeloma

(1:36)

¿Yeshua bajó del cielo o es un hombre como todos? El Judaísmo de Yeshua CAP 8 Parte 2

(1:51:54)

True Christianity: Identifying the Light (2 John 1-6) | Jon Benzinger | Light in the Darkness

(41:15)

Same God - Elevation Worship ft. Jonsal Barrientes (Lyrics)

(8:2)

Un Dia A La Vez - Paulino Bernal and Ricardo Mejia

(3:57)

CAR T-Cell Therapies | High Impact Topic (HIT)

(5:18)

Federico Arreola advierte que el PRI le teme a Ricardo Mejía Berdeja en Coahuila

(6:9)

Same God | Elevation Worship (Ft. Jonsal Barrientes) | Divine Expressions | 240317S

(18:36)

Cevostamab Shows Promise in Hard-to-Treat Multiple Myeloma: Early CAMMA 2 Trial Results

(7:49)

The future in multiple myeloma: BiTE immunotherapy, CAR-T, and immune checkpoint inhibitors

(21:41)

Dr. Berdeja on Updated Data With bb21217 in Multiple Myeloma

(1:29)

Jesus Berdeja, MD, discusses the evolving role of CAR-T therapies in multiple myeloma

(40)

Dr. Berdeja Discusses Anticipated Research in Multiple Myeloma

(1:32)

Dr. Berdeja Discusses the Future of Treatment for Myeloma

(1:6)

Clinical Activity of BMS-986393, a CAR T cell therapy directed at GPRC5D, in Pts with RRMM

(8:6)

Dr. Berdeja on Updated CARTITUDE-1 Results With JNJ-4258 in Multiple Myeloma

(59)

Copy of Dr. Berdeja Discusses Anticipated Research in Multiple Myeloma

(26)

Dr. Berdeja on Next Steps With JNJ-4528 in Relapsed/Refractory Myeloma

(1:20)

Dr. Berdeja on FDA Approval of Frontline Daratumumab Plus VMP in Multiple Myeloma

(38)

Use of Bispecifics and CAR T cells in South America

(4:51)

Toxicity profile for CAR T-cells in multiple myeloma

(2:42)

Dr. Berdeja on Treatment of Patients With Newly Diagnosed Myeloma

(1:58)